Amylyx (AMLX) CEO Justin Klee Sells Shares

What Happened

• Justin B. Klee, Chief Executive Officer of Amylyx Pharmaceuticals (AMLX), sold a total of 30,464 shares on September 10, 2026 in two open-market dispositions. He sold 29,025 shares at a weighted average price of $32.13 for proceeds of $932,553, and 1,439 shares at a weighted average price of $33.16 for proceeds of $47,710 — total proceeds ≈ $980,263. These were sales (dispositions), not purchases.

Key Details

• Transaction date: 2026-09-10; Form 4 filed: 2026-09-14 (filed within normal Form 4 timing for a weekend span).
• Prices/ranges: 29,025 shares sold at a $32.13 weighted average (individual trades ranged $31.81–$32.75); 1,439 shares sold at a $33.16 weighted average (individual trades ranged $32.87–$33.39).
• Footnotes: The larger 29,025-share sale was automatic to cover tax withholding on vested performance stock units (tax-withholding sale). The reported prices are weighted averages; the filing notes the per-trade price ranges and that full breakdowns can be provided to the SEC on request.
• Shares owned after the transactions: not specified in the provided excerpt of the filing.

Context

• These sales were at least partly automatic to satisfy tax withholding related to the vesting of performance stock units, per the filing — a routine administrative sale rather than necessarily a discretionary signal about company prospects. Sales to cover withholding are common for equity-compensated executives and do not necessarily indicate negative sentiment.